前收市價 | 4.20 |
開市 | 5.65 |
買盤 | 4.80 |
賣出價 | 5.70 |
拍板 | 40.00 |
到期日 | 2024-08-16 |
今日波幅 | 5.65 - 5.65 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 338 |
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.